摘要
抗肿瘤药物分级管理是规范抗肿瘤药物临床使用管理,提高合理用药水平的核心环节。国家卫生健康委员会发布的《抗肿瘤药物临床应用管理办法(试行)》要求各地制定本区域内的抗肿瘤药物分级管理目录。此外《,抗肿瘤药物临床合理应用管理指标(2021年版)》也需要各地区有一个统一的分级管理目录。基于此,广西药学会循证药学专业委员会组织多学科专家对抗肿瘤药物的分级管理目录、处方权限等热点内容进行研讨,结合广西实际,最终形成专家共识,为广西区内医疗机构做好抗肿瘤药物的分级管理提供指导。
Graded management of antineoplastic drugs is the core link to regulate the management of clinical use of antineoplastic drugs and improve the level of rational drug use.“The Administrative Measures for the Clinical Application of Antineoplastic Drugs(Trial)”issued by the National Health Commission of the People ’s Republic of China requires each region to formulate a graded management catalog of antineoplastic drugs in the region. In addition,“the Management Indicators for the Rational Clinical Use of Antineoplastic Drugs(2021 Edition)”also requires a unified graded management catalog for each region. Based on this, the Evidence-based Pharmacy Professional Committee of Guangxi Pharmaceutical Association organized multidisciplinary experts to discuss the hot topics such as the graded management catalog of antineoplastic drugs and prescription authority, and finally formed an expert consensus in combination with the reality of Guangxi, so as to provide guidance for the graded management of antineoplastic drugs in medical institutions in Guangxi.
作者
广西药学会循证药学专业委员会
张宏亮
蒋能
黄光明
Evidence-based Pharmacy Professional Committee of Guangxi Pharmaceutical Association
出处
《广西医科大学学报》
CAS
2023年第1期166-172,共7页
Journal of Guangxi Medical University
基金
国家自然科学基金资助项目(No.82060801)
广西医科大学第一附属医院临床研究攀登计划青年科技启明星计划(No.YYZS2021005)
广西医科大学第一附属医院优秀医学英才培养计划。
关键词
抗肿瘤药物
分级管理
专家共识
antineoplastic drugs
graded management
expert consensus
